BioCentury
ARTICLE | Clinical News

Latanoprost punctal plug delivery system: Phase II data

December 3, 2012 8:00 AM UTC

Data from all patients with open-angle glaucoma or ocular hypertension regardless of plug loss (n=77) in the open-label, U.S. Phase II PPL GLAU 13 trial showed that a blank plug in the lower punctum and 95 µg latanoprost delivered via a punctal plug in the upper punctum (regimen A) reduced mean IOP from baseline to week 4, the primary endpoint, by 4.8 mmHg. Treatment consisting of no plug in the lower punctum and 95 µg latanoprost in the upper punctum (regimen B) reduced mean IOP by 4.4 mmHg at week 4, while treatment consisting of 95 µg latanoprost in the lower punctum and a blank plug in the upper punctum (regimen C) reduced mean IOP by 5.1 mmHg at week 4. On secondary endpoints, regimen A reduced mean IOP by 4.7 mmHg at week 8 and 4.3 mmHg at week 12; regimen B reduced mean IOP by 4.2 mmHg at week 8 and 4.2 mmHg at week 12; and regimen C reduced mean IOP by 4.9 mmHg at week 8 and 5.1 mmHg at week 12. ...